AZENT

A PHASE IIA CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF OSIMERTINIB (AZD9291) IN FIRST-LINE PATIENTS WITH EGFR MUTATION-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AND CONCOMITANT EGFR T790M MUTATION AT TIME OF DIAGNOSIS.

THE PRIMARY GOAL IS TO EVALUATE THE EFFICACY OF OSIMERTINIB (AZD9291), IN TERMS OF THE OBJECTIVE RESPONSE RATE IN PATIENTS WITH ADVANCED NON-SQUAMOUS NSCLC WITH EGFR MUTATIONS AND THE EGFR T790M MUTATION AT DIAGNOSIS AS DEFINED BY RECIST 1.1 CRITERIA.

SAFETY AND EFFICACY WILL ALSO BE MEASURED.

 
AZENT AT CLINICALTRIALS.GOV